Marks offered his resignation while citing Kennedy’s “misinformation and lies” and an “unprecedented assault on scientific truth” impacting public health.

Peter Marks’ ouster comes at a time when the sector is already suffering through a years-long public markets slump.

Vaccine makers were hit particularly hard yesterday, as Marks’ resignation letter alluded to disagreements with HHS Secretary Robert F. Kennedy Jr. on vaccines. Moderna’s stock dropped 9%, while Vaxcyte’s plummeted 46% (though shares of Vaxcyte were also affected by disappointing results of a vaccine candidate.)

As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency is heading for the exit. | In resigning as director of the FDA’s Center for Biologics Evaluation and Research,

Amid a dramatic reshaping of the federal healthcare apparatus, the FDA has named an acting leader of its Center for Biologics Evaluation and Research. | Amid a dramatic reshaping of the federal healthcare apparatus,

Dr. Peter Marks, the top vaccine official at the Food and Drug Administration, wrote in a letter that he was resigning from his position.

Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.

The U.S. Food and Drug Administration said on Tuesday it had named Scott Steele as acting director of its Center for Biologics Evaluation and Research (CBER), following the exit of top vaccine scientist Peter Marks.

Dr. Peter Marks, the top vaccine regulator at the U.S. Food and Drug Administration, was forced to resign, citing Health and Human Services Secretary Robert F. Kennedy Jr.'s "misinformation and lies" around immunization.

The U.S. Food and Drug Administration's top vaccine official, Peter Marks, has been pushed out, the Wall Street Journal reported on Friday. Marks, who played a key role in U.S. President Donald Trump's first term in developing COVID-19 vaccines,